Detailed Information on Publication Record
2015
Evaluation of Cell-Free Urine microRNAs Expression for the Use in Diagnosis of Ovarian and Endometrial Cancers. A Pilot Study
ZÁVESKÝ, Luděk, Eva JANDÁKOVÁ, Radovan TURYNA, Lucie LANGMEIEROVÁ, Vít WEINBERGER et. al.Basic information
Original name
Evaluation of Cell-Free Urine microRNAs Expression for the Use in Diagnosis of Ovarian and Endometrial Cancers. A Pilot Study
Authors
ZÁVESKÝ, Luděk (203 Czech Republic), Eva JANDÁKOVÁ (203 Czech Republic), Radovan TURYNA (203 Czech Republic), Lucie LANGMEIEROVÁ (203 Czech Republic), Vít WEINBERGER (203 Czech Republic, guarantor, belonging to the institution), Lenka ZÁVESKÁ DRÁBKOVÁ (203 Czech Republic), Martina HŮLKOVÁ (203 Czech Republic), Aleš HOŘÍNEK (203 Czech Republic), Daniela DUŠKOVÁ (203 Czech Republic), Jaroslav FEYEREISL (203 Czech Republic), Luboš MINÁŘ (203 Czech Republic, belonging to the institution) and Milada KOHOUTOVÁ (203 Czech Republic)
Edition
Pathology & Oncology Research, Dordrecht, Springer, 2015, 1219-4956
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30214 Obstetrics and gynaecology
Country of publisher
Netherlands
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 1.940
RIV identification code
RIV/00216224:14110/15:00083502
Organization unit
Faculty of Medicine
UT WoS
000360385400023
Keywords in English
ovarian cancer; endometrial cancer; urine; microRNA;miR-92a; miR-106b
Tags
Tags
International impact, Reviewed
Změněno: 16/12/2015 17:04, Soňa Böhmová
Abstract
V originále
Among gynaecological cancers, epithelial ovarian cancers are the most deadly cancers while endometrial cancers are the most common diseases. Efforts to establish relevant novel diagnostic, screening and prognostic markers are aimed to help reduce the high level of mortality, chemoresistance and recurrence, particularly in ovarian cancer. MicroRNAs, the class of post-transcriptional regulators, have emerged as the promising diagnostic and prognostic markers associated with various diseased states recently. Urine has been shown as the source of microRNAs several years ago; however, there has been lack of information on urine microRNA expression in ovarian and endometrial cancers till now. In this pilot study, we examined the expression of candidate cell-free urine microRNAs in ovarian cancer and endometrial cancer patients using quantitative real-time PCR. We compared the expression between pre- and post-surgery ovarian cancer samples, and between patients with ovarian and endometrial cancers and healthy controls, within three types of experiments. These experiments evaluated three different isolation methods of urine RNA, representing two supernatant and one exosome fractions of extracellular microRNA. In ovarian cancer, we found miR-92a significantly up-regulated, and miR-106b significantly down-regulated in comparison with control samples. In endometrial cancer, only miR-106b was found down-regulated significantly compared to control samples. Using exosome RNA, no significant de-regulations in microRNAs expression could be found in either of the cancers investigated.We propose that more research should now focus on confirming the diagnostic potential of urine microRNAs in gynaecological cancers using more clinical samples and largescale expression profiling methods.